Abstract:Background: Huntington's disease (HD) is a genetic neurological disorder predominantly characterised by the progressive loss of GABAergic medium spiny neurons in the striatum resulting in motor dysfunction. One potential strategy for the treatment of HD is the development of cell replacement therapies to restore neuronal circuitry and function by the replacement of lost neurons. We propose the generation of lineage-specific human lateral ganglionic eminence precursors (hiLGEP) using direct reprogramming technology provides a novel and clinically viable cell source for cell replacement therapy for HD. Methods: hiLGEPs were derived by direct reprogramming of adult human dermal fibroblasts (aHDFs) using chemically modified mRNA (cmRNA) and a defined reprogramming medium. hiLGEPs were differentiated in vitro using an optimised striatal differentiation medium. Acquisition of a striatal precursor and neural cell fate was assessed through gene expression and immunocytochemical analysis of key markers. hiLGEP-derived striatal neuron functionality in vitro was demonstrated by calcium imaging using Cal-520. To investigate the ability for hiLGEP to survive, differentiate and functionally integrate in vivo, we transplanted hiLGEPs into the striatum of quinolinic acid (QA)-lesioned rats and performed behavioural assessment using the cylinder test over the course of 14 weeks. Survival and differentiation of hiLGEPs was assessed at 8 and 14-weeks post-transplant by immunohistochemical analysis. Results: We demonstrate the capability to generate hiLGEPs from aHDFs using cmRNA encoding the pro-neural genes SOX2 and PAX6, combined with a reprogramming medium containing Go6983, Y-27632, N-2 and Activin A. hiLGEPs generated functional DARPP32+ neurons following 14 days of culture in BrainPhys(TM) media supplemented with dorsomorphin and Activin A. We investigated the ability for hiLGEPs to survive transplantation, differentiate to medium spiny-like striatal neurons and improve motor function in the QA lesion rat model of HD. Fourteen weeks after transplantation, we observed STEM121+ neurons co-expressing MAP2, DARPP32, GAD65/67, or GABA. Rats transplanted with hiLGEPs also demonstrated reduction in motor function impairment as determined by spontaneous exploratory forelimb use when compared to saline transplanted animals. Conclusion: This study provides proof-of-concept and demonstrates for the first time that aHDFs can be directly reprogrammed to hiLGEPs which survive transplantation, undergo neuronal differentiation to generate medium spiny-like striatal neurons, and reduce functional impairment in the QA lesion rat model of HD.

Generation of induced pluripotent stem cell line, ICGi033-A, by reprogramming peripheral blood mononuclear cells from a patient with Huntington's disease

Establishment of an Induced Pluripotent Stem Cell Line (Zjulli004-A) from a Hypertrophic Cardiomyopathy Patient Carrying MYBPC3/c.3764C>A Mutation

Establishment of Induced Pluripotent Stem Cell Line (Zzui009-A) from an Alzheimer's Disease Patient Carrying a PSEN1 Gene Mutation

Generation of Induced Pluripotent Stem Cell Line (Zzui007-A) from a 52-Year-old Patient with a Novel CHCHD2 Gene Mutation in Parkinson's Disease.

Generation of an Induced Pluripotent Stem Cell Line (Zjulli003-A) from a Hypertrophic Cardiomyopathy Patient Carrying MYH7/c.4384G > A Mutation

Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons

Induced Pluripotent Stem Cells in Huntington’s Disease: Disease Modeling and the Potential for Cell-Based Therapy

Generation of an induced pluripotent stem cell line (KNIHi001-A) by reprogramming peripheral blood mononuclear cells isolated from a patient with Parkinson's disease

Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins.

Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice

Induced neural stem cells as a means of treatment in Huntington’s disease

Progerin-Induced Transcriptional Changes in Huntington's Disease Human Pluripotent Stem Cell-Derived Neurons

Generation of Induced Pluripotent Stem Cell Line, ZJUCHi002-A, from Charcot-Marie-Tooth Disease Type 2A (CMT2A) Patient with a Mutation of C.752c>t in MFN2

Human-induced pluripotent stem cell line (FDHSi001-A) derived from a patient with a CGG repeat expansion in the 5'UTR of GIPC1

Generation of Human-Induced Pluripotent Stem Cells in the Absence of Exogenous Sox2

Generation of naivetropic induced pluripotent stem cells from Parkinson's disease patients for high efficiency genetic manipulation

Generation of iPSC line (FMCPGHi003-A) from human PBMCs of a patient with Familial hemiplegic migraine type 3

Generation of Human-Induced Pluripotent Stem Cells from Peripheral Blood Mononuclear Cells of C9ORF72-Associated Amyotrophic Lateral Sclerosis Patients

Reprogrammed Human Lateral Ganglionic Eminence Precursors Generate Striatal Neurons and Restore Motor Function in a Rat Model of Huntington's Disease.

Generation of an induced pluripotent stem cell line (SDQLCHi067-A) from a patient with subcortical band heterotopia harboring a heterozygous mutation in DCX gene

Generation of induced pluripotent stem cells (CSSi017-A)(12862) from an ALS patient carrying a repeat expansion in the C9orf72 gene